AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial.<h4>Aims</h4>This study conducted a comprehensive analysis of the association between AID expression and clinical outcomes in 70 Indonesian patients with DLBCL treated with a standard CHOP ± rituximab regimen.<h4>Methods and results</h4>Immunostaining results showed that AID was expressed in 35.7% of DLBCL samples. Here, AICDA is linked to diffuse large B-cell lymphoma.